Detalhe da pesquisa
1.
Final report of TKI discontinuation trial with dasatinib for the second attempt of treatment-free remission after failing the first attempt with imatinib: Treatment-free Remission Accomplished by Dasatinib (TRAD) study.
Br J Haematol
; 203(5): 781-791, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37697469
2.
BCR-ABL1 transcript doubling time as a predictor for treatment-free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase.
Br J Haematol
; 196(1): 136-145, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34496035
3.
Toward optimization of cyclosporine concentration target to prevent acute graft-versus-host disease following myeloablative allogeneic stem cell transplant.
Clin Transplant
; 36(8): e14732, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35606904
4.
Optimal duration of imatinib treatment/deep molecular response for treatment-free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial.
Br J Haematol
; 193(4): 779-791, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33876423
5.
Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia.
Blood
; 131(8): 855-863, 2018 02 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-29203585
6.
A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia.
Blood
; 129(24): 3165-3174, 2017 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28336527
7.
Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma.
Blood
; 129(24): 3175-3183, 2017 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28468797
8.
Cumulative incidence of subsequent malignancy after allo-HCT conditioned with or without low-dose total body irradiation.
Blood Adv
; 6(3): 767-773, 2022 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34995342
9.
Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results.
Leukemia
; 36(1): 90-99, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34316017
10.
Clinical outcome of chronic myeloid leukemia patients who switch from first-line therapy with a second generation tyrosine kinase inhibitor to an alternative TKI.
Leuk Res
; 111: 106674, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34333277
11.
Antirelapse effect of pretransplant exposure to rabbit antithymocyte globulin.
Blood Adv
; 3(9): 1394-1405, 2019 05 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-31043372
12.
Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide.
Biol Blood Marrow Transplant
; 14(9): 993-1003, 2008 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-18721762
13.
The predictive value of intracellular imatinib levels in newly diagnosed chronic myeloid leukemia.
Leuk Res
; 88: 106285, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31846781
14.
Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma.
Blood
; 107(12): 4623-7, 2006 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16467197